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MicroRNA-34a dependent regulation of AXL
controls the activation of dendritic cells in
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Current treatments for rheumatoid arthritis (RA) do not reverse underlying aberrant immune
function. A genetic predisposition to RA, such as HLA-DR4 positivity, indicates that dendritic
cells (DC) are of crucial importance to pathogenesis by activating auto-reactive lymphocytes.
Here we show that microRNA-34a provides homoeostatic control of CD1cþ DC activation via
regulation of tyrosine kinase receptor AXL, an important inhibitory DC auto-regulator. This
pathway is aberrant in CD1cþ DCs from patients with RA, with upregulation of miR-34a and
lower levels of AXL compared to DC from healthy donors. Production of pro-inflammatory
cytokines is reduced by ex vivo gene-silencing of miR-34a. miR-34a-deficient mice are
resistant to collagen-induced arthritis and interaction of DCs and T cells from these mice are
reduced and do not support the development of Th17 cells in vivo. Our findings therefore
show that miR-34a is an epigenetic regulator of DC function that may contribute to RA.
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D
endritic cells (DC) are sentinels of the immune system
that initiate and direct the immune response
towards foreign antigens while inducing tolerance to
self-antigens1. Numerous studies have shown that altered DC
function can promote breach of tolerance to self-antigens and
development of autoimmunity and inflammation2–4.
Rheumatoid arthritis (RA) is the most common autoimmune
polyarthritis, with a lifetime risk of 3.6% in women and 1.7% in
men5,6, causing pain, disability, impaired quality of life and
reduced life expectancy. Genetic, epigenetic and epidemiological
studies suggest that autoimmunity lies at the core of RA
pathogenesis. RA is particularly associated with breach of
tolerance to post-translationally modified self-proteins, usually
via citrullination or carbamylation, often predating clinical
disease by years7–9. These early events are initiated by DCs that
stimulate auto-reactive T and B cells8,10,11, which thereafter
orchestrate progression to chronic joint inflammation,
destruction and comorbidity12,13. The majority of current RA
treatments target inflammation; however, partial or non-response
is common and sustained remission occurs in a minority of
patients, representing a considerable unmet clinical need.
For example, tumour necrosis factor (TNF), interleukin-6 (IL-6)
receptor (IL-6R) and JAK inhibitors reduce inflammation, and
slow down radiographic progression, but do not generally
mediate restoration of immune homeostasis14,15. Moreover,
current approaches targeting the adaptive immune response via
B cell depletion and co-stimulatory molecule blockade do not
seem to promote tolerance16. Therefore, restoring homoeostatic
DC function to achieve tolerance would be a compelling strategy
for treatment of RA.
Accordingly, we sought to dissect molecular pathways that
drive the activation of RA DCs. DCs can be broadly categorized
into plasmacytoid and myeloid (conventional) lineages. Human
myeloid DCs comprise CD141þ , CD16þSLANþ , CD16þ
SLAN and CD1cþ cells17,18. In addition, ‘inflammatory DCs’
can differentiate from monocytes infiltrating inflammatory tissues
and show phenotypic overlap (for example, CD1c expression)
and function with conventional CD1cþ 18 DCs, although
the latter cells differentiate from a distinct precursor19. Human
conventional CD1cþ DCs and inflammatory DC populations are
critical for T helper type 17 (Th17) responses (for example, via
IL-23, IL-6, IL-1b) and pro-inflammatory TNF production,
particularly upon TLR7/8 stimulation20–24. The activation of
DCs is controlled by multiple negative-feedback loops25–27. TAM
receptor family containing tyrosine kinase receptors Tyro3, AXL
and MERTK are critical in switching off TLR ligand-induced DC
activation26. Recently, a constitutive AXL expression that was
associated with a lower level of major histocompatibility class
(MHC) class II was identified as a feature of a distinct
subpopulation of human conventional CD1cþ DCs28.
CD1cþ DC from RA patients show activated phenotype. RA
synovial fluid contains both conventional CD1cþ and
inflammatory CD1cþ cells that can prime naive T cells29–31.
In addition, these cells support synovial inflammation
by producing TNF upon stimulation with TLR7/8 ligands23,32,33,
and human transgenic TLR8 mice develop spontaneous arthritis
due to constitutive activation of DCs that drive autoimmunity34.
Environmental factors such as smoking strongly influence risk
of developing RA, suggesting that epigenetic mechanisms are
involved in RA pathogenesis35. MicroRNAs are epigenetic
regulators that fine-tune complex molecular pathways by
mediating mRNA degradation or translation inhibition based
on 6–8 nucleotide (nt) complementarity sequences between
microRNA and the 30-untranslated region (UTR) of target
mRNAs36. Aberrations in miRNA control mechanisms
contribute to the development of autoimmune diseases,
including arthritis37–39. Herein we describe a role for miR-34a
in driving deregulation of DC function in inflammatory arthritis.
Results
miR-34a is upregulated in CD1cþ DCs from RA patients.
To identify molecular pathways that are deregulated in
RA myeloid cells at the site of pathology, we previously generated
a transcriptomic signature of RA synovial fluid (SF) myeloid cells
and found key upregulation of miR-34a compared to matched
cells from blood40. As miR-34a is enriched in DCs41,42, we
hypothesised that miR-34a has a regulatory role in DC function
and thereby in the pathogenesis of RA. MiR-34a (chromosome
1p36) and family-members miR-34b/c (co-transcribed from
11q23) have similar functions but have distinct expression
patterns43. To investigate the expression of miR-34a and c in
RA CD1cþ cells, we purified CD1cþ DCs (sorting strategy in
Supplementary Fig.1) from peripheral blood (PB) of healthy
donors and from PB and SF from RA patients with established
RA (42 years from diagnosis). Blood CD1cþ DCs from RA
patients had greater miR-34a expression than healthy donors, and
this was further increased in SF DCs (Fig. 1a). Elevated miR-34a
expression was also observed in blood DCs from patients with
early RA (o6 months from diagnosis) (Fig. 1b). MiR-34c was
expressed only at low levels and was not significantly
differentially expressed across disease or tissue and was not
further examined (Fig. 1a).
DCs primarily function within lymph node structures or
the tissue. We therefore investigated the expression of miR-34a in
CD1cþ cells from synovial tissue of patients with elevated disease
activity (mean±s.d. DAS28: 5.07±0.68) and compared it to
the cells from their PB and to PB cells from age-matched healthy
donors. MiR-34a was strongly upregulated in CD1cþ sorted from
RA synovial tissues compared to RA PB and healthy PB cells
(Fig. 1c). This analysis of an independent patient cohort confirmed
an increase expression of miR-34a in RA PB CD1cþ compared to
age-matched healthy donors PB cells, and revealed that the highest
fold change in PB and synovial tissue was among patients
resistant-to-treatment and positively correlated with disease
duration (r¼ 0.543; P¼ 0.016; Pearson Correlation Coefficient).
An evaluation of miR-34a expression in blood and synovial tissue
CD1cþ cells from patients with comparator inflammatory joint
disease, psoriatic arthritis (PsA) showed no significant changes in
the blood but an increase in expression in synovial tissue DCs
although to a lesser degree than in RA (P¼ 0.02; Kruskal–Wallis
with Dunn’s multiple comparison test; Supplementary Fig. 2).
Demographic and clinical information for both sets of RA patients;
and PsA patients is presented in Supplementary Tables 1 and 2.
Collectively, these data suggest a potential role for miR-34a in the
regulation of DCs function in RA.
We next investigated the regulation of miR-34a expression in
CD1cþ DCs. MiR-34a was highest in CD1cþ cells from SF and
synovial tissues, which contains both conventional CD1cþ and
monocyte-derived CD1cþ cells; therefore, we compared the
expression of miR-34a in monocytes and monocyte-derived DCs.
The copy number of miR-34a in blood monocyte subsets
(CD14þCD16 , CD14dimCD16þ and CD14þCD16þ ) from
healthy donors was low (Fig. 2a,b), but increased significantly
when they were differentiated to inflammatory CD1cþ DCs by
granulocyte macrophage colony-stimulating factor (GM-CSF),
which was also reflected by a fold-change as compared to
monocytes at day 0 (Fig. 2c). The miR-34a levels in these day 7
immature CD1cþDCs were rapidly downregulated upon
maturation with ligands CL097 for intracellular TLR7/8
and lipopolysaccharide (LPS) for surface TLR4 (Fig. 2d). Thus,
miR-34a can be induced during GM-CSF-triggered DC
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differentiation and then undergoes dynamic regulation upon DC
maturation suggesting a potential role in this process. We next set
out to explore the role of miR-34a in DC activation and its impact
on arthritis.
miR-34a / mice have reduced antigen-induced arthritis.
We explored a functional role for miR-34a in experimental
arthritis using a collagen-induced model in which DCs play a key
pathogenic role. Compared to wild-type (WT), miR-34a /
mice had reduced incidence and severity of arthritis (Fig. 3a,b)
accompanied by reduced histopathological articular
inflammation and damage (Fig. 3c,d). Serum cytokine profiling
revealed selectively reduced IL-17 concentrations (Fig. 3e)
suggesting a role for miR-34a in the generation of
IL-17-producing, auto-reactive T lymphocytes that drive experi-
mental arthritis44,45. There was no difference in concentration of
the prototypical Th1 or Th2 cytokines, IFNg (P¼ 0.18;
Mann–Whitney u-test) and IL-5 (P¼ 0.08; Mann–Whitney
u-test), respectively, nor in the production of collagen-specific
antibodies (Supplementary Fig. 3).
To address the specific role of miR-34a in DC-driven
antigen-specific T lymphocyte activation, we adoptively trans-
ferred naive OVA-specific OT-II T lymphocytes (congenic
CD45.1 background) to WT and miR-34a / recipients and
challenged them with OVA antigen as outlined on Fig. 3f.
MiR-34a / and WT recipients had similar numbers of total
antigen-specific CD4þ and CD4þ INFgþ cells but miR-34a /
mice showed a selective reduction in antigen-specific Th17 cell
numbers (Fig. 3g,h and gating strategy in Supplementary Fig. 4).
Collectively, these data suggest that miR-34a expression is
important in the development of experimental arthritis, in part
via DC-driven expansion of Th17 cells.
miR-34a regulates DC activation by targeting AXL. To dissect
the specific contribution of miR-34a to DC function in the
context of T cell priming and joint inflammation, we evaluated
MHC class II, co-stimulatory and inhibitory molecules and a
broad range of soluble mediators in miR-34a / and control
WT bone marrow derived DCs (gating in Supplementary Fig. 5A)
stimulated with various TLR ligands. MiR-34a / DCs
produced less pro-inflammatory TNF (Fig. 4a), and cytokines
implicated in the differentiation (IL-6 and IL-1b) and expansion
(p40 subunit of IL-12/IL23 and p19 subunit of IL-23) of
Th17 cells (Fig. 4a and Supplementary Fig. 5B). In addition,
miR-34a / DCs had reduced upregulation of MHC class II
surface expression compared to WT DCs upon maturation with
TLR ligands. There was no significant difference in the surface
expression of co-stimulatory molecules CD86, CD40 and
inhibitory PD-L1 molecule (Fig. 4b,c), as well as in expression of
candidate adhesion molecules ICAM-1, CD11c, CD11b and
CD18a (Supplementary Fig. 6). To test the impact of reduced
expression of MHC class II on DC–T-cell interaction, we
analysed the contact area between fluorescently labelled OTII T
cells (carboxyfluorescein succinimidyl ester (CFSE)-green) and
WT or miR-34a / DCs (CMTPX-red) in the presence of
antigen using a high content image analyser (IN Cell Analyzer
2000) (Fig. 4d). This showed that the increased interaction
between DCs and T cells associated with antigen and enhanced
with TLR ligand was significantly reduced in miR-34a /
compared to WT DC co-cultures (Fig. 4d,e).
To extend the studies to the clinical setting, we first
over-expressed miR-34a in blood monocyte-derived inflammatory
DCs from healthy donors to mimic the constitutively raised
miR-34a expression in RA CD1cþ DCs (Fig. 1), and stimulated
them with LPS or CL097. MiR-34a over-expression increased DC
activation as demonstrated by an increase in their TNF production
(Fig. 4f). Consistent with this, inhibition of endogenous miR-34a by
gene-silencing during TLR stimulation of monocyte-derived DCs
decreased TNF, p40 (IL-12/IL23) and IL-6 production (Fig. 4g).
This pro-inflammatory role for miR-34a was confirmed in
conventional PB CD1cþ DCs sorted from RA patients in
which gene-silencing of miR-34a-inhibited TLR-mediated TNF
production (Fig. 4h).
Together these data indicate that miR-34a can regulate DC
function, firstly for antigen presentation via modulating class II
expression and secondly by promoting pro-inflammatory and Th17
responses. These data were consistent with the reduced develop-
ment of antigen-specific Th17 response and limited onset and joint
pathology of antigen-induced arthritis in miR-34a / mice.
To explore mechanisms whereby miR-34a regulated DC
activation, we firstly performed in silico analysis of predicted
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Figure 1 | MiR-34a expression is upregulated in DCs from patients with RA. (a) CD1cþ DCs were FACS-sorted from PB of healthy donors (HD, n¼6),
and from PB (n¼6) and SF (n¼6) of RA patients with established RA of42 years duration. Compared to HD, miR-34a expression was upregulated in PB
CD1cþ in RA patients (*Po0.05, Mann–Whitney U-test); and further upregulated in matched SF (**Po0.01, paired t-test). There was no significant
difference (ns) in miR-34c expression between these groups. (b) miR-34a expression was upregulated in PB CD1cþ cells in patients (n¼ 14) with early RA
o6 months from diagnosis (eRA), as compared to age-matched HD (n¼6) (*Po0.05, Kolmogorov–Smirnov test). (c) MiR-34a expression was
upregulated in CD1cþ DCs FACS sorted from dispersed RA synovial membrane (SM, n¼ 9) as compared to RA PB (n¼ 19) and HD PB (n¼ 10) cells
(**Po0.01 Kruskal–Wallis test and Dunn’s multiple comparison test). Data presented as median and inter-quartile range boxplots; and for c, each dot
represents single sample from naive (naive-to-treatment); MTX resistant (resistant to methotrexate treatment); TNFi resistant (resistant to combined
therapy of methotrexate and TNF inhibitors). Demographic and clinical information for samples in a–b is presented in Supplementary Table 1 (Cohort 1);
and for samples in c is presented in Supplementary Table 2 (Cohort 2). ns, nonsignificant.
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and validated conserved mouse and human miR-34a mRNA
targets (TargetScan, n¼ 416). To map targets to those expressed
in cells of myeloid origin we overlapped this with the transcripts
present in RA synovial myeloid cells40. This strategy identified 43
putative myeloid-cell relevant miR-34a targets (Fig. 5a). This
included AXL, a tyrosine kinase receptor and member of the
TAM receptor family (TYRO3, AXL, MERTK). We chose to
investigate AXL because it has been shown to function as a key
inhibitory DC auto-regulator by induction of SOCS1/3 and
TWIST1 upon binding its ligand Gas6 (refs 26,46–49).
We confirmed that Axl-deficient DCs show enhanced activation
upon stimulation by TLR ligands manifested by an increased
expression of MHC class II and production of IL-6 and TNF
compared to WT cells (Supplementary Fig. 7).
We validated whether miR-34a directly targets human AXL
mRNA using a reporter assay. A luciferase plasmid containing
AXL 30-UTR in ‘sense’ but not in ’anti-sense’ orientation showed
reduced luciferase activity after transfection with miR-34a mimic
(Fig. 5b). Similarly, transfection of human monocyte-derived DCs
with miR-34a mimic or inhibitor, repressed or de-repressed AXL
mRNA expression, respectively (Fig. 5c). To investigate whether
the relationship between miR-34a and its target Axl is reciprocal,
murine WT bone marrow derived DCs were stimulated with LPS,
and expression levels of both were evaluated at different
time points. miR-34a was downregulated by LPS at 24 h, whereas
Axl mRNA was upregulated but then decreased at later time
points, corresponding with the recovery of miR-34a expression
(Fig. 5d). Moreover, immature bone marrow derived DCs of
miR-34a / mice, and human monocyte-derived DCs
transfected with miR-34a inhibitor expressed higher levels of
AXL protein compared to WT cells, or to cells transfected with
control inhibitor, as shown by Western blot (Fig. 5e,f and
Supplementary Fig. 8). This was associated with a higher surface
expression of Axl in miR-34a / DCs in the immature state and
during maturation with TLR ligands. Maturation of WT DCs led
to an increased surface expression of Axl at 24 h, followed by a
decline at 48 h. Expression of Axl in miR-34a / DCs was
higher than WT cells at all time points (Fig. 5g). This was
associated with a decrease in soluble GAS6 levels in miR-34a /
cultures as compared to controls upon LPS stimulation suggesting
that there might be an enhanced binding of GAS6 to increased
levels of Axl on miR-34a / DCs50 (Supplementary Fig. 9A).
Consistent with these findings, Axl and its downstream mediator
Socs-3 (ref. 26) were upregulated while inflammatory mediators
IL-23 (p19) downregulated in the joint tissue of miR-34a /
compared to WT mice with experimental arthritis (Fig. 5h,i and
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Supplementary Fig. 9B). Together, these data demonstrate that
AXL is under the epigenetic control of miR-34a in DCs.
To test whether AXL is responsible for the miR-34a-mediated
phenotype of human DC, we transfected human monocyte-derived
DCs with miR-34a inhibitor or control inhibitor in the presence of
AXL siRNA or control siRNA. Inhibition of miR-34a led to a
significant reduction of DC activation, as shown by decreased TNF
production, which was restored by downregulation of AXL by
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siRNA (Fig. 6a,b). This demonstrates that at least some facets of DC
activation regulated by miR-34a are AXL-dependent.
AXL expression is reduced in RA CD1cþ DCs. Since CD1cþ
DCs of RA patients had high expression levels of miR-34a, we
next investigated the mRNA expression of AXL in these CD1cþ
cells and found reduced AXL expression in two RA cohorts
(Fig. 6c,d) that correlated negatively with the expression of
miR-34a (r¼  0.463; P¼ 0.04; Pearson correlation coefficient).
The reduced AXL expression was associated with an increased
activation of RA DCs as shown by an elevated expression level of
IL-6 (r¼  0.560; P¼ 0.04; Pearson correlation coefficient)
(Fig. 6e). This suggests that RA DCs have an epigenetically
deregulated homoeostatic mechanism that would normally limit
DCs activation preventing inflammation and autoimmunity26.
We also sought to evaluate other components of the AXL
pathway. Serum concentrations of the endogenous ligand of
AXL; GAS6, and its decoy receptor soluble AXL (sAXL) which
is an inhibitor of the cellular AXL/SOCSs pathway, were
measured in RA patient groups: naive-to-treatment (n¼ 20),
resistant-to-treatment (n¼ 20), in remission (n¼ 10), and in
patients with osteoarthritis (n¼ 10) and age-matched healthy
donors (n¼ 10). Demographic and clinical information for these
cohorts is presented in Supplementary Table 3. We found no
difference in serum GAS6 levels in any group of patients
compared to healthy donors. The serum concentrations of sAXL
in OA were similar to those of healthy donors. In contrast, soluble
AXL was upregulated in the naive-to-treatment and resistant-to-
treatment RA groups compared to healthy donors (P¼ 0007 and
0.0042, respectively; Kruskal–Wallis with Dunn’s multiple
comparison test), with the highest concentration of sAXL
detected in the naive-to-treatment group. RA in remission
showed a nonsignificant increase in serum concentration of
sAXL compared to healthy donors (P¼ 0.156; Kruskal–Wallis
with Dunn’s multiple comparison test) (Supplementary Fig. 10).
Thus, elevated levels of serum sAXL in RA could be associated
with underlying autoimmunity and to a lesser extent
inflammation.
In summary, the reduced levels of cell-associated AXL receptor
in patients’ DCs and higher serum concentrations of GAS6 decoy
receptor (sAXL) may prevent engagement of GAS6-AXL
inhibitory pathway in RA DCs, particularly in naive-to-treatment
early RA.
Discussion
Current treatments for RA cannot cure damaged joints or
re-establish immunological homeostasis8,15,16. The genetic loci
linked to RA, for example, HLA-DR4 (DRB1*0401) (refs 10,13)
suggest that DCs are of crucial importance to pathogenesis by
initiating the activation, migration and differentiation of
citrullinated protein-specific, auto-reactive Th1, Th17 and
follicular helper T cells. These subsequently support the
production of auto-antibodies by B cells. Autoimmunity is then
followed by localization of the inflammatory response to the
joints8. The intrinsic biology of DCs encompasses the potential to
re-instate immune homeostasis1. In support of this concept, a
phase I clinical trial demonstrated improvement in DAS28
in RA patients transfused with autologous tolerogenic DCs
modified in vitro with an NF-kB inhibitor51, and this was
associated with a decrease in antigen-specific effector T cells and
serum pro-inflammatory cytokines, and an increase in regulatory
T cells. A similar study with intra-articular delivery of autologous
tolerogenic DCs showed stabilization of knee symptoms52. Thus,
a better understanding of the regulatory mechanisms operating in
DCs of RA could help development next generation DC-based
therapies. We found a negative-feedback control of DC activation,
mediated by miR-34a governing immunosuppressive AXL
pathway activation, that is aberrant in circulating, SF and
synovial tissue CD1cþ DCs of RA patients; and that also
contributes to experimental arthritis.
We demonstrated that miR-34a is expressed in conventional
human CD1cþ cells, and in monocyte and bone marrow derived
inflammatory DCs. Mildner et al.42 also found its expression in
mouse conventional DCs. MiR-34a expression was induced by
GM-CSF during differentiation from precursor to inflammatory
DCs. Hashimi et al. showed that in these immature human
inflammatory DCs, miR-34a supports endocytosis by regulating
the JAG1/Wnt1 pathway enhancing antigen uptake41. We
showed here that during maturation of inflammatory DCs with
TLR ligands, that leads to their activation, miR-34a is rapidly
downregulated allowing the re-emergence of its epigenetic target
AXL which then terminates the activation of DCs. AXL, along
with two other members of the TAM receptor family (TYRO3
and MERTK) are key receptors that in response to binding
their ligands GAS6 or Protein S produced by innate cells26 or
expressed on the surface of activated T cells (Protein S)48
terminate both the inflammatory and the adaptive immune
response by inducing SOCS1/3 and TWIST1 in order to reinforce
homoeostasis. When this is aberrant, for example, in
TAM-deficient mice, this leads to spontaneous chronic
inflammation and autoimmunity, including production of
anti-collagen antibodies and inflammatory histopathology in
joints, gut, skin and central nervous system46–48,53. The
fundamental importance of this regulatory pathway has also
been demonstrated in cancer54 in which reduced expression of
miR-34a due to promoter methylation leads to over-expression of
AXL thereby promoting an immunosuppressive environment
contributing to poor prognosis55,56. We found the opposite in RA
patients that contributed to RA DC activation thus potentially
creating an autoimmune-hypersensitive environment.
In RA patients circulating CD1cþ DCs have constitutively
upregulated miR-34a associated with decreased AXL expression.
In addition, RA patients have increased serum concentrations of
Figure 3 | MiR-34a / mice are resistant to arthritis. (a–e) WT (n¼ 15) and miR-34a / (n¼ 14) mice were sensitized according to the protocol in
Methods. Mice were monitored for disease onset and paw swelling from day 10. Mice were killed on day 33 and tissue samples harvested.
(a,b) miR-34a / mice had a reduced incidence (a) and severity (b) of arthritis; Po 0.05 two-way ANOVA; severity data are presented as mean±s.d.
(c,d) miR-34a / mice had reduced joint pathology. (c) Representative histology of typical WT and miR-34a / joints. Tissue sections (WT, n¼ 15;
miR-34a / , n¼ 14) were stained with trichrome (cartilage and bone collagen stained turquoise) and H&E (red; inflammatory synovium).
(d) Quantitative evaluation of synovial inflammation, and cartilage and bone degradation showed reduced scores for miR-34a / mice.
(e) MiR-34a / CIA mice showed reduced concentrations of IL-17 in the serum compared to WT, but no difference in interferon-gamma (IFNg) or
interleukin (IL)-5. Data are presented as dot-plots with median; (d,e) *Po0.05, Mann–Whitney u-test. (f) Schematic description of the adoptive transfer of
OT-II OVA-specific T cells into WT (n¼ 13) and miR-34a / (n¼ 13) mice. (g,h) After adoptive transfer of OVA-specific T cells, miR-34a / mice
showed reduced development of antigen-specific IL-17-producing cells compared to WT recipients. Representative dot-plot representation (g) and
quantitative evaluation (h) of total antigen-specific cells and IL-17/IFNg producing cells in WT and miR-34a / recipients are shown. *Po0.05,
Mann–Whitney U-test. Data are presented as median±IQR obtained in two independent experiments. ns, not significant.
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Figure 4 | MiR-34a drives DC activation. (a) miR-34a / DCs show reduced production of pro-inflammatory cytokines. Bone marrow DCs fromWTand
miR-34a / mice (n¼6 pooled) were stimulated with LPS or CL097 for 24 h. (b,c) miR-34a / DCs show reduced expression of MHC class II. WTand
miR-34a / DCs were stimulated as in a for 24 h and the expression of co-stimulatory molecules was evaluated as median fluorescent index (MFI) by
flow cytometry. Representative MFI expression of MHC class II (b), and quantitative expression of MHC class II, co-stimulatory (CD40 and CD86), and
inhibitory (PD-L1) molecules is shown (c). *Po0.05 Mann–Whitney u-test between genotypes. Data are presented as mean±s.e.m. of 4–6 replicates from
two independent experiments. (d,e) miR-34a / DCs show a reduced interaction with antigen-specific T cells. CMTPX-labelled WT and miR-34a /
DCs were co-cultured with CFSE-labelled OT-II CD4þ T cells at 1:1 or 1:3 ratios in the presence of OVA peptide or OVA plus LPS for 24. The contact area
was analysed with In Cell Analyzer 2000. Representative pictures of 1:1 cultures (d) and quantitative evaluation (e) presented as mean±s.e.m. of % of
overlapping areas between DC and Tcells compared to the total cell surface area (six technical replicates in total) are shown. *Po0.05 between conditions,
&Po0.05 between genotypes, two-way ANOVA followed by Tukey’s multiple comparison test or unpaired t-test. (f,g) miR-34a regulates pro-inflammatory
cytokine production by human DCs. (f–h) Healthy donor monocyte-derived inflammatory DCs (n¼4–5) were transfected with miR-34a mimic (34am) or
miR-34a inhibitor (34i) or appropriate controls (Cm¼mimic or Ci¼ inhibitor); and (g) DCs (conventional CD1cþ DCs; n¼ 7) were sorted from RA
patients’ blood and transfected with miR-34a inhibitor (34i) or control inhibitor (Ci). The DCs were then stimulated with LPS or CL097 for 24 h.
(f) Enforced expression of miR-34a increased TNF production; *Po0.05, Kruskal–Wallis followed with Dunn’s multiple comparison tests or paired t-test.
(g,h) miR-34a inhibitor reduced the production of cytokines by healthy donor monocyte-derived DCs (g) and sorted PB RA CD1cþ DCs (h). *Po0.05
paired t-test. (f,g) Data are presented as mean±s.e.m of 4–7 biological replicates obtained in separate experiments. ANOVA, analysis of variance.
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soluble AXL that could function as a decoy receptor for the AXL
ligand, GAS6. Ex vivo production of pathogenic cytokines, for
example, TNF by circulating RA CD1cþ was reduced by
inhibition of endogenous miR-34a expression, whereas
mimicking the phenotype of RA DCs by increasing miR-34a in
DC from healthy donors enhanced TLRs induced TNF
production. In vivo miR-34a deficiency led to attenuation of
antigen-induced experimental arthritis that was associated with
an increased expression of the miR-34a target pathway Axl/Socs-3
in joint tissue. Consistent with this observation, recent pre--
clinical therapeutic studies showed that local and systemic
overexpression of GAS6 and Protein S could ameliorate
experimental arthritis57. In vitro miR-34a / DCs had
constitutively increased levels of AXL and decreased production
of pro-inflammatory cytokines (for example, TNF), and Th17
inducing cytokines (for example, IL-6, IL-1b and IL-23) that drive
joint pathology. A similar DC phenotype was observed upon
active inhibition of endogenous miR-34a in human activated DCs
in vitro. In addition to the role in regulation of pro-inflammatory
mediators, miR-34a supported MHC class II expression, and
miR-34a / DCs had reduced surface MHC class II in
immature state and limited upregulation upon maturation. This
suggests that miR-34a levels in mature DCs may regulate the
signal strength of the MHC/T-cell receptor synapse that controls
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Figure 5 | MiR-34a controls DC activation by regulating AXL. (a) Epigenetic miR-34a mRNA targets relevant to myeloid cell biology were identified by
integrating the conserved miR-34a targets generated by the prediction algorithm TargetScan (Probability of conserved targeting value 40.4) in a Venn
diagram along with the mRNA transcriptomic signature of RA SF myeloid cells68. (b,c) AXL is targeted by miR-34a. (b) Luciferase reporter assay for AXL
shows a reduction in luciferase activity when cells were transfected with miR-34a mimic (details in Methods). Data are presented as mean±s.e.m of three
technical replicates and is representative of two independent experiments. *Po0.05, paired t-test between AXL sense and anti-sense. (c) AXL mRNA
expression is regulated by miR-34a in monocyte-derived DCs in vitro. DCs transfected with either miR-34a mimic (34am) or miR-34a inhibitor (34ai) or
appropriate controls (Cm¼mimic; Ci¼ inhibitor), had decreased or increased AXL expression, respectively, after 24 h. Data are presented as mean±s.e.m.
of three biological replicates; *Po0.05, Mann–Whitney U-test. (d) miR-34a downregulation during LPS-induced mouse bone marrow DC maturation is
associated with an increase in Axl mRNA at 24hr. Data presented as mean±s.e.m of three technical replicates. (e) GM-CSF differentiated mouse
miR-34a / DCs contain higher concentrations of total AXL protein compared to WT as demonstrated by western blot. (f) Healthy donor human PB
monocyte-derived DCs transfected with miR-34a inhibitor (34ai) showed higher expression levels of AXL compared with cells transfected with control
inhibitor (Ci). (g) miR-34a / DCs express higher levels of membrane AXL compared to WTcontrol DCs measured by FACS. WTand miR-34a / bone
marrow DCwere cultured in medium (control) or stimulated with LPS (1 ngml 1) for 24 and 48 h and AXL expression evaluated as MFI by cytometry. Data
presented as mean±s.e.m of four biological replicates from two independent experiments. (h–i) miR-34a / had higher levels of Axl (h) and Socs-3
(i) mRNA in joint tissue compared with WT at day 33 of CIA. Data presented as dot-plots with median lines. *Po0.05, Mann–Whitney U-test.
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the activation of T cells; in particular Th17 and Th1 which
require a strong T-cell receptor signal58. This was confirmed by
observation of decreased interaction between miR-34a / DCs
and antigen-specific T cells. Commensurate with ex vivo and
in vitro phenotypes upon miR-34a manipulation, deficiency of
miR-34a in antigen-presenting cells resulted in the lack of
development of antigen-specific Th17 cells, confirmed by low
serum concentrations of IL-17; and an attenuated joint pathology
in miR-34a / mice during experimental arthritis.
We observed that miR-34a expression in circulating CD1cþ
DCs is already increased in some patients with early RA, (r6
months since diagnosis) as compared to healthy donors,
suggesting a role in the onset of disease. The question remains
what triggers this increase. The miR-34a promoter is abundant in
CpG islands suggesting that environmental factors driving
demethylation of the promoter59,60 is a plausible epigenetic
mechanism of regulation as first reported in cancer59. In addition,
the miR-34a promoter has STAT3-binding sites54 and a
IL-6/STAT3 gene signature was found to be enriched in
circulating T cells of early RA patients61.
In summary, we describe herein that miR-34a controls AXL, a
tyrosine kinase receptor that governs the termination of DC
activation and contributes to the development of experimental
arthritis. In RA patients, sustained expression of high levels of
microRNA-34a in CD1cþ DCs inhibits cellular AXL expression
and this, together with an increased level of decoy receptor
soluble AXL in serum, may render DCs more sensitive to
maturation signals, which can cause DCs to support auto-reactive
T cells (Fig. 7).
Thus, modulating the miR-34a/AXL pathway in RA DCs by
using miR-34a inhibitors or AXL agonist could be a feasible
therapeutic strategy to restore homoeostasis and promote
resolution of RA.
Methods
Patients and healthy donors. For the evaluation of miR-34 and AXL mRNA
expression in PB, SF and synovial tissue, samples were obtained from healthy
donors, RA patients and PsA patients at Rheumatology clinics (Glasgow, UK) and
from the Division of Rheumatology, Fondazione Policlinico Universitario A.
Gemelli, Catholic University of the Sacred Heart (Rome, Italy). RA patients met the
2010 ACR/EULAR diagnostic criteria62. Demographic and clinical information for
three cohorts used in the study are detailed in Supplementary Tables 1 and 2. In
cohort 1, healthy donors were younger than RA patients, however age was
unrelated to miR-34a and AXL expression (r¼  0.080, P¼ 0.736 and r¼ 0.434,
P¼ 0.056, respectively; Pearson correlation coefficient). For the evaluation of GAS6
and sAXL, the concentrations of GAS6 and sAXL were quantified in sera of healthy
donors, RA patients and OA patients by commercial enzyme-immunoassay (R&D
System, DuoSets: Dy154 and Dy885). Demographic and clinical information are
detailed in Supplementary Table 3. The study protocol was approved by the local
Ethics Committee of the Catholic University of the Sacred Heart and by the West
of Scotland Research Ethical Committee (11/S0704/7). All the donors provided
signed informed consent.
Human DC cultures. CD14þ monocytes from PB were isolated using CD14þ
micro-beads (#130050201/Miltenyi Biotec) and Auto-MACS separator according
to the manufacturer’s protocol. Monocyte purity evaluated by flow cytometry was
typically 496%. For their differentiation to inflammatory DCs, monocytes were
cultured in complete medium (RPMI 1640, 10% fetal calf serum, 2mM glutamine,
100Uml 1 penicillin, 100 mgml 1 streptomycin; Life Technologies) with
GM-CSF (100 ngml 1) and IL-4 (20 ngml 1; both from Peprotech) for 6-7
days and the DC phenotype was confirmed by their expression of CD11c
(#337216/PE/Cy7 anti-human CD11c), CD1c (#331524/APC anti-human CD1c)
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Figure 6 | AXL expression is constitutively reduced in RA CD1cþ DCs. (a,b) The miR-34a-dependent production of TNF by DCs is mediated by AXL.
Healthy donor (n¼ 7) monocyte-derived DCs were transfected with a combination of miR-34a inhibitor or AXL siRNA or control inhibitor or siRNA for 16 h,
and then stimulated with CL097 (1 mgml 1) for 24 h. (a) Representative experimental data for TNF production; mean±s.d. of 3 biological replicates from
one donor. (b) Summary of the relative production of TNF from all 7 donors tested; each normalised to the TNF production by DCs transfected with Control
inhibitor (Ci) plus Control siRNA (C siRNA). Po0.05 Kruskal–Wallis with Dunn’s multiple comparison test. (c–e) CD1cþ DCs in RA patients show
decreased expression of AXL mRNA and increase expression of IL-6. (c) CD1cþ DCs were FACS-sorted from blood of healthy donors (HD, n¼ 17) and RA
patients with established disease (RA, n¼ 15; cohort 1 described in Supplementary Table 1); and d,e CD1cþ DCs were FACS-sorted from age-matched
healthy donors (n¼ 11) and RA patients with early and established disease (n¼ 19, cohort 2 described in Supplementary Table 2). AXL (c–d) and IL-6 (e)
mRNAs were evaluated by qPCR. Data are presented as dot-plots with median lines. *Po0.05, Mann–Whitney U-test.
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and MHC class II (#307642/Brilliant Violet 785 anti-human HLA-DR; all
antibodies from BioLegend; dilution 1: 100) by cytometry. The conventional
CD1cþ population from PB of RA and healthy donors, and from RA and PsA SF
and synovial tissue were sorted by FACSAria III according to the sorting strategy
presented in Supplementary Figure 1. In preparation for flourescence-activated cell
sorting (FACS), SF was overlaid on Histopague-1077 (Sigma) and centrifuged
(2,100 r.p.m., 25min) to obtain mononuclear cells. Synovial tissues were
obtained using ultrasound-guided synovial tissue biopsy of the knee following the
published protocol63. Briefly, all patients underwent ultrasound evaluation of the
knee using an ultrasound machine with a multifrequency linear transducer (MyLab
Twice, Esaote). Using the ultrasound view, the best point of entrance for the needle
was identified on the lateral margin of the suprapatellar recess. Each patient was
provided with a face-mask and cap and the whole procedure was undertaken under
sterile conditions. Skin disinfection was done with iodine solution (performed
twice, starting from the point of needle entrance up to 25 cm proximally and
distally). Arthrocentesis of the knee joint was performed using the lateral
suprapatellar access if joint effusion was present. The skin, subcutaneous tissue and
joint capsule was anaesthetised with 10ml lidocaine 2%. Next, a 14G needle
(Precisa 1410-HS Hospital Service Spa, Italy) was inserted into the joint. Regions
of synovial hypertrophy were identified under grey-scale guidance to ensure
sampling of representative synovial tissue. All the synovial tissue specimens
obtained (at least eight pieces for each analysis) were placed on a nonwoven
wet gauze for collection63.
Synovial biopsies were cut into small pieces and digested with Liberase
Research Grade, in RPMI (150 mgml 1 Roche) with rotation in 37 C for 1.5 h.
Digested tissue was passed through a 100mm tissue-strainer and washed once
with PBS/2%FCS/2mM EDTA. FACS-analysis of single cell suspensions was
performed after staining with Fixable Viability Dye eFluor 780 (#65086514/
ThermoFisher Scientific; dilution 1:1,000) to exclude dead cells. Cells were then
incubated (4 C 30min) with antibody-conjugates, which were from BioLegend
and used in 1:100 dilution. These included #307642/Brilliant Violet 785
anti-human HLA-DR, #337216/PE/Cy7 anti-human CD11c, #344104/PE
anti-human CD141, #331524/APC anti-human CD1c, #302040/Brilliant Violet
605 anti-human CD16, #304050/Brilliant Violet 711 anti-human CD45, #323004/
fluorescein isothiocyanate (FITC) anti-human CD15 (SSEA-1), #302206/FITC
anti-human CD19, #304604/FITC anti-human CD56, #313232/FITC anti-human
CD117, #300440/FITC anti-human CD3 and #301822/Alexa Fluor 700 anti-human
CD14. The gating strategy was based on fluorescence minus one and unstained
controls (Supplementary Fig 1). Briefly, dead and CD56, CD3, CD19, CD15,
CD117 and CD14 lineage-positive cells were excluded, and MHC class IIþ
CD11cþ cells gated. The CD1cþ population was gated based on the lack of CD141
and CD16 and the presence of CD1cþ expression. CD1cþ cells were then FACS-
sorted into tubes with complete media. Blood monocytes were sorted based on
their lack of CD2 (#309208/BioLegend; dilution 1:10), CD15 (#323006/BioLegend;
dilution 1:10), CD19 (#302208/BioLegend; dilution 1:10), CD56 (#130090755/
Miltenyi Biotec; dilution 1:100) and NKp46 (#331908/BioLegend; dilution 1:20)
and the presence of MHC class II (#307633/BioLegend; dilution 1:50). The MHC
class IIþ cells were then gated based on the expression of CD14 (#325608/
BioLegend; dilution 1:20) and CD16 (#302006/BioLegend; dilution 1:20); resulting
in three monocyte populations CD14þCD16 ; CD14þCD16þ ,
CD14dimCD16þ . Sorted DCs and monocytes were used for cell culture
experiments or were immediately lysed with Qiagen buffer and RNA isolated with
micro-miRNAeasy kit (#217084) or miRNeasy mini Kit (#217004) according to the
manufacturer’s protocol (Qiagen). Cultured DCs in complete medium were
transfected either with miR-34a inhibitor or control inhibitor (both at 20 nM;
Qiagen) or with miR-34a mimic or control mimic (C. elegans miR-67), both at
20 nM (Dharmacon) using DharmaFECT 3 transfection reagent (ThermoFisher
Scientific). For some experiments, DCs were transfected with AXL-specific siRNA
or All Stars Negative Control siRNA (40 nM, both from Qiagen). To monitor
transfection efficiency DCs were transfected with Dy547-labelled mimic or All Stars
Negative Control siRNA labelled with Alexa Fluor 488. After 16 h, cells were
stimulated with LPS (1 ngml 1) or CL097 (1mgml 1, both from InvivoGen) and
cells and supernatant were collected after 24 h. In all experiments, the transfection
efficiency of siRNA and microRNA mimic was checked by flow cytometry and only
when 460% of cells were positive were they used for further analysis.
Mice. MicroRNA-34a gene-deficient (miR-34a / ) mice on a C57BL/6
background were purchased from Jackson Laboratories64. WT littermates were
obtained by backcrossing miR-34a / mice with C67BL/6 mice (Jackson Labs).
Axl / mice and WT littermates C57BL/6 (B6Nq; Johan Ba¨cklund; Karolinska
Institute, Sweden) were bred and maintained in a pathogen-free facility at
University of Glasgow. Procedures were approved by University of Glasgow Ethical
Committee and the UK Home Office (project licence 60/4430). In vivo experiments
were conducted on males age 8–12 weeks. In vitro experiments were conducted on
cells from males and females age 8–12 weeks.
Collagen-induced arthritis. To induce collagen-induced arthritis, mice were
injected intradermally with type II chicken collagen emulsified in Freund’s
complete adjuvant (200 mg in 0.2ml. MD BioSciences) on day 0. On day 21, type II
chicken collagen/PBS (200 mg in 0.2ml) was injected i.p65. Mice were monitored
for development of arthritis by microcaliper measurements of paw swelling. In
addition, a clinical severity score was used in which 0¼ no reaction; 1¼mild but
definite redness and swelling of the ankle/wrist/digits; 2¼moderate-to-severe
redness and swelling of the ankle/wrist; 3¼ redness and swelling of the entire paw
including digits; and 4¼maximally inflamed limb with involvement of multiple
joints66. Mice were killed on day 33 and cells and tissues harvested. Two
researchers measured paw swelling (one of them blind); and both evaluated
histology sections blind to experimental condition.
Adoptive transfer of OT-II T cells. OT-II T cells on a CD45.1 background (at 0.5
and 1.5 106) were injected into the tail vain of WT and miR-34 / mice on day
0. On day 1, mice were injected with 100mg of OVA peptide or PBS per mouse
(Cambridge Reserved Biochemical) in complete Freunds adjuvant (0.5mgml 1;
Sigma) in 0.2ml into the right leg muscle. On day 6, mice were culled, the draining
lymph nodes harvested and dispersed cells re-stimulated with PMA/ionomycin
(50/500ngml 1; Sigma) overnight in the presence of Golgi Stop (Life
Technologies), and analysed for the intracellular production of IL-17, IFN-g and
IL-5 using fluorescently labelled antibodies (#559502/PE anti-mouse IL-17A;
BD Pharmingen; #505810/APC anti-mouse IFNg; BioLegend; #504311/BV421
anti-mouse IL-5; BioLegend; all in 1:50 dilution and Fix/Perm kit according to
protocols (#420801 and # 421002, BioLegend).
Mouse DC culture. Bone marrow cells from WT and miR-34a / mice were
cultured with GM-CSF (20 ngml 1, PeproTech) at a concentration of 0.2
106ml 1 in 10ml of complete medium in petri dishes. After 3 and 6 days the
medium was replaced with fresh medium supplemented with GM-CSF. On day 8,
cells were seeded into 24-well culture plates at a concentration of 0.25 106ml 1
and stimulated with LPS (1 ngml 1) or CL097 (1 mgml 1). Cells and culture
supernatant were collected at various time points for analysis of cytokine
production, cell surface markers and AXL protein. For some in vitro experiments
CD11bþCD4þ spleen cells were isolated with CD4þ DC isolation kit
(#130091262/Miltenyi Biotec).
Evaluation of DC/T cell interaction with IN Cell Analyzer 2000. Spleens were
isolated from OTII transgenic mice and prepared into single cell suspensions and
treated with 5ml of 1 red blood cell lysis buffer (eBioscience) for 5min at RT.
CD4þ T cells were isolated from splenocytes by negative selection (#130095248/
Miltenyi Biotec). Bone marrow derived WT and miR-34a / DCs and CD4þ T
cells were re-suspended at a density of 107 cells per ml in serum-free RPMI-1640
GM-CSFR
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GAS6
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Figure 7 | A model describing miR-34/AXL function in DCs. The
expression of miR-34a increases during CD1cþ DC differentiation (1) and
epigenetically down-regulates AXL expression (2). DC maturation, by TLR
ligation, induces DC activation, for example, MHC class II upregulation and
cytokine production. This maturation signal also down-regulates miR-34a
(3), which then de-represses AXL, which in turn induces SOCSs and
terminates DC activation (4), thus providing homeostatic feedback control
of DC activation. In RA patients, sustained expression of high levels of
miR-34a in CD1cþ DCs inhibits AXL expression and may render DCs more
sensitive to maturation signals, which can cause DCs to support sustained
auto-reactive T-cell activation.
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medium and labelled with Cell Tracker Red CMTPX or CFSE cell tracer kits
(#C34552 and #C34554 respectively; Molecular probes) at 7.5 mM, respectively,
for 10min in a 37 C incubator. After incubation, cells were washed by cen-
trifugation at 300 g for 5min at 4 C three times in RPMI medium containing
10% FCS to deactivate the dye. DCs and CD4þ T cells were co-cultured in
384-well m-clear tissue culture treated micro-plates (Greiner) at ratios of 1:1 (8.000
of each cell type) or 1:3 with ovalbumin peptide (OVA) at 1 mgml 1; with or
without lipopolysaccharide (LPS) at 100 ngml 1 for 24 h.
Image acquisition. IN Cell Analyzer 2000 is a lamp-based high content analysis
system equipped with a large chip CCD camera (Photometrics CoolSNAP K4)
allowing for whole-well imaging. The Nikon  10 magnifying objective with flat
field and apochromatic corrections (plan Apo), chromatic aberration-free infinity
(CF160) and 0.45 numerical aperture (NA) was used. Cells were imaged at 37 C
and 2D images of CFSE-labelled CD4þ T cells were acquired in the FITC channel
using 490/ 20 excitation, 525/36m emission. CMTPX-labelled DCs in the
TexasRed (TR) channel were acquired using 555/ 25 excitation and 605/52m
emission. One tile was imaged per well covering B20% of the well area. Images
acquired by the IN Cell Analyzer 2000 were analysed using the Developer Toolbox
software V1.9.2 (GE Healthcare). Data are shown as representative screenshots of a
384-well or the percentage of OTII T cells that overlap with DCs.
Western blot for AXL. Bone marrow derived DCs were seeded in complete media
into six-well plates (1 106 per well). Human PB monocyte-derived DCs (1 106
per well) were transfected with control or miR-34a inhibitor (both 50 nM, Qiagen).
After 24 h (mouse DCs) or 48 h (human DCs) whole-cell lysates were prepared
using M-PER (ThermoFisher Scientific) lysis buffer. Lysate samples (10 mg protein)
were run on a 4–12% SDS–polyacrylamide gel electrophoresis gel, followed by
transfer to polyvinylidene difluoride membrane and incubation with either goat
anti-mouse AXL (1:200 dilution, #/AF854/R&D Systems), rabbit anti-human AXL
(1:500 dilution, #8661S/Cell Signaling Technology), or anti-mouse/human b-actin
control (1 mgml 1, #3c-81178/Santa Cruz Biotechnology).
Flow cytometry of DC surface markers. Expression of DC surface markers was
evaluated by LSR-II cytometer (BD Bioscience) using the following antibodies:
anti-MHC class II-PE-Cy7 (#107629/BioLegend) or APC-Cy7 (#107628/BioLe-
gend) anti-CD11c-FITC (#117306/BioLegend) or PerCP-Cy5.5 (#560584/BD
Pharmingen), anti-CD86-PerCP (#105025/BioLegend), anti-CD40-Pacific Blue
(#124626/BioLegend), anti-PD-DL-1-Qdot-605 (#124321/BioLegend), ICAM-1-
FITC (#11054182/eBioscience), CD18-PE (#101408/BioLegend), CD69-PE-Cy7
(#25069182/eBioscience), CD11a-APC (#101120/BioLegend), CD44-e450
(#48044182/eBioscience), CD11b BV605 (#83011242/eBioscience; all used in 1:100
dilution), and anti-AXL-APC (#FAB8541A/R&D Systems; dilution 1:20). The dead
cells were excluded with Fixable Viability Dye eFluor 780 or e506 (#650866/
ThermoFisher Scientfic). There was no difference in viable cell proportion of BM-
derived DCs between WT and miR-34a / genotypes (mean±s.d: 75%±12 and
71% ±10, respectively).
AXL 30-UTR Luciferase assay. Human AXL 30-UTR in sense or anti-sense
orientation were cloned downstream of the Renilla Luciferase gene in pmiRGLO
vector (Promega). HEK293 cells were co-transfected with 0.2 mg pmiRGLO
containing sense or anti-sense AXL 30-UTR and 40 nM miR-34a mimic or
scrambled mimic control, using Attractene (Qiagen). Luciferase activity was
measured 24 h later using the Dual-GLO Luciferase assay system (#E2920/
Promega)67.
Quantitative PCR. Total DC RNA was extracted using a miRNeasy mini Kit
(#217004) or micro-miRNAeasy kit (#217084) (both from Qiagen). For microRNA
analysis, cDNA was transcribed from RNA using either a miScript Reverse
Transcription Kit II (#218160 Qiagen) or TaqMan microRNA Reverse
Transcription Kit (#4366596/Life Technologies). For mRNA analysis, a High
Capacity cDNA Reverse Transcription Kit was used (#4368814/ThermoFisher
Scientific). TaqMan mRNA or miRNA assays (Life technologies) or miScript
primer assays (Qiagen) were used for semi-quantitative determination of the
expression of miR-34a (Hs000426 Life Technologies; MS00001428 Qiagen),
miR-34c (Hs000428), Let7a (Hs000377, U6B snRNA (Hs001973; MS00033740),
TNF Mm00443258_m1), AXL (Hs01064444_m1, Mm00437221_m1), Socs3
(Mm00545913_s1), p19 (Mm00518984_m1), IL-6 (Hs00174131_m1) and 18S
(Hs03003631_g1) with miRScript SybR Green PCR kit (#218073/Qiagen) or
TaQman Gene Expression master mixes (Life Technologies). In some experiments
miR-34a copy number was evaluated. Known copy numbers of synthetic miR-34a
mimic and housekeeping let7a (both from Dharmacon) were used to prepare a
standard curve of serial 10-fold dilutions in nuclease-free water (range from
1 109 to 1 103 copies). Each of these standards was used alongside cDNA from
the samples in qPCR (miScript Sybr Green PCR kit) with specific human miR-34a
and let7a primers (Qiagen) on a 7900HT TaqMan reader. Based on the standard
curves, the copy number of miR-34a and let7a the samples were calculated and data
were presented as the copy number of miR-34a per 10,000 copies let7a. In some
experiments, the expression of miR-34a is presented as a relative value (i) 2DCT,
where DCt¼Cycle threshold for RNU6 (housekeeping) minus Ct for miR-34a or
(ii) fold change, where DCt for selected control condition¼ 1 or 100%.
To compare miR-34a and AXL expression in synovial CD1cþ DCs with blood
CD1cþ DCs, amplification of cDNA was necessary due to the small number of
CD1cþ DCs obtained from synovial biopsies (mean cell number: 2,000 cells) by
FACS-sorting. Equal numbers of blood, SF and synovial tissue CD1cþ DCs were
used and RNA isolated (cohort 2; Supplementary Table 2). RNA was divided into
two aliquots for separate transcription into cDNA with either High Capacity
Reverse Transcription kit (#4368814/ThermoFisher Scientific) to evaluate AXL
expression or with miScript Reverse Transcription Kit II (#218160/Qiagen) to
evaluate miR-34a expression. In the next step, cDNA for AXL, IL-6 and
housekeeping 18S were amplified with PreAmp Master kit (#4391128/
ThermoFisher Scientific) and cDNA for RNU6, miR-34a were amplified with
miScript PreAMP PCR Kit (#331452/Qiagen) followed by standard qPCR as
described above.
Luminex and enzyme immuno-assays. The concentration of cytokines and
chemokines in mouse and human DC culture supernatants was quantified by
immuno-fluorescence assay using a 20-plex cytokine assay (LMC0006; Invitrogen)
on a Bio-Plex platform (Bio-Rad) or using paired antibodies ELISAs (mouse and
human TNF, #CHC3013 and #CHC1753/Life Technologies; mouse IL-23
(#88723088/ ThermoFisher Scientific) and mouse GAS6 (#DY986/R&D
Systems)66.
Statistical analysis. The data were analysed by Graph Pad Prism version 5.0 and
Minitab 17 software. Data was summarized as mean±s.d./s.e.m. or median±IQR,
and between-group differences were tested by t-test, by paired t-test or by
Mann–Whitney u-test, or Kolmogorov–Smirnov test, depending on data
distribution, or by ANOVA or Kruskal–Wallis tests with correction for multiple
comparisons. Correlation between normally distributed continuous variables was
tested using the two-tailed Pearson Correlation Coefficient. A P-value o0.05 was
considered significant.
Data availability. The data that support the findings of this study are available
from the corresponding author upon request.
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